PL3027594T3 - 2-benzoylaminobenzamide derivatives as bcl-3 inhibitors - Google Patents
2-benzoylaminobenzamide derivatives as bcl-3 inhibitorsInfo
- Publication number
- PL3027594T3 PL3027594T3 PL14744880.7T PL14744880T PL3027594T3 PL 3027594 T3 PL3027594 T3 PL 3027594T3 PL 14744880 T PL14744880 T PL 14744880T PL 3027594 T3 PL3027594 T3 PL 3027594T3
- Authority
- PL
- Poland
- Prior art keywords
- benzoylaminobenzamide
- bcl
- inhibitors
- derivatives
- benzoylaminobenzamide derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1313664.3A GB201313664D0 (en) | 2013-07-31 | 2013-07-31 | Bcl-3 inhibitors |
| PCT/EP2014/066564 WO2015014972A1 (en) | 2013-07-31 | 2014-07-31 | 2-benzoylaminobenzamide derivatives as bcl-3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3027594T3 true PL3027594T3 (en) | 2023-01-02 |
Family
ID=49167238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14744880.7T PL3027594T3 (en) | 2013-07-31 | 2014-07-31 | 2-benzoylaminobenzamide derivatives as bcl-3 inhibitors |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10450285B2 (en) |
| EP (1) | EP3027594B1 (en) |
| JP (3) | JP2016525561A (en) |
| CN (2) | CN110016003A (en) |
| AU (1) | AU2014298433B2 (en) |
| BR (1) | BR112016002027A2 (en) |
| CA (2) | CA3130003C (en) |
| DK (1) | DK3027594T3 (en) |
| ES (1) | ES2930138T3 (en) |
| GB (1) | GB201313664D0 (en) |
| HK (1) | HK1226072A1 (en) |
| PL (1) | PL3027594T3 (en) |
| PT (1) | PT3027594T (en) |
| RU (1) | RU2016103654A (en) |
| WO (1) | WO2015014972A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201313664D0 (en) * | 2013-07-31 | 2013-09-11 | Univ Cardiff | Bcl-3 inhibitors |
| US10273218B2 (en) | 2014-07-31 | 2019-04-30 | University College Cardiff Consultants Limited | BCL-3 inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US261781A (en) * | 1882-07-25 | Edwin b | ||
| US693255A (en) * | 1901-05-25 | 1902-02-11 | Stiles Fry | Washing-machine. |
| US929966A (en) * | 1908-01-24 | 1909-08-03 | Charles L Merry | Mounting for eyeglasses. |
| CA2057324A1 (en) * | 1990-12-18 | 1992-06-19 | Lora Louise Fitch | Benzamide and sulfonamide hypoglycemic agents |
| US20040006011A1 (en) * | 1996-07-12 | 2004-01-08 | Gour Barbara J. | Peptidomimetic modulators of cell adhesion |
| GB9717576D0 (en) * | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
| JP2001162950A (en) * | 1999-12-13 | 2001-06-19 | Fuji Photo Film Co Ltd | Heat sensitive recording material |
| AU2001231154A1 (en) * | 2000-01-24 | 2001-07-31 | Adherex Technologies Inc. | Peptidomimetic modulators of cell adhesion |
| MY138097A (en) * | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
| CA2532965C (en) | 2003-07-22 | 2013-05-14 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| SE0401342D0 (en) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds |
| WO2006012577A2 (en) | 2004-07-22 | 2006-02-02 | Bayer Pharmaceuticals Corporation | Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake |
| US7569725B2 (en) * | 2004-10-21 | 2009-08-04 | Britsol-Myers Squibb Company | Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| JP2009543770A (en) * | 2006-07-14 | 2009-12-10 | アステックス・セラピューティクス・リミテッド | Combinations of pyrazole derivatives for the inhibition of CDK and GSK |
| US20090318430A1 (en) * | 2006-07-21 | 2009-12-24 | Astex Therapeutics Limited | Medical use of cyclin dependent kinases inhibitors |
| WO2009054468A1 (en) * | 2007-10-24 | 2009-04-30 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
| JP2011507910A (en) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | Methods for changing the lifetime of eukaryotes |
| GB201313664D0 (en) * | 2013-07-31 | 2013-09-11 | Univ Cardiff | Bcl-3 inhibitors |
| US10273218B2 (en) * | 2014-07-31 | 2019-04-30 | University College Cardiff Consultants Limited | BCL-3 inhibitors |
-
2013
- 2013-07-31 GB GBGB1313664.3A patent/GB201313664D0/en not_active Ceased
-
2014
- 2014-07-31 CA CA3130003A patent/CA3130003C/en active Active
- 2014-07-31 BR BR112016002027A patent/BR112016002027A2/en not_active Application Discontinuation
- 2014-07-31 AU AU2014298433A patent/AU2014298433B2/en active Active
- 2014-07-31 DK DK14744880.7T patent/DK3027594T3/en active
- 2014-07-31 PT PT147448807T patent/PT3027594T/en unknown
- 2014-07-31 CN CN201910112421.6A patent/CN110016003A/en active Pending
- 2014-07-31 EP EP14744880.7A patent/EP3027594B1/en active Active
- 2014-07-31 CN CN201480054341.5A patent/CN105705496A/en active Pending
- 2014-07-31 RU RU2016103654A patent/RU2016103654A/en unknown
- 2014-07-31 JP JP2016530542A patent/JP2016525561A/en active Pending
- 2014-07-31 US US14/908,035 patent/US10450285B2/en active Active
- 2014-07-31 ES ES14744880T patent/ES2930138T3/en active Active
- 2014-07-31 PL PL14744880.7T patent/PL3027594T3/en unknown
- 2014-07-31 CA CA2919976A patent/CA2919976C/en active Active
- 2014-07-31 WO PCT/EP2014/066564 patent/WO2015014972A1/en active Application Filing
-
2016
- 2016-12-21 HK HK16114491A patent/HK1226072A1/en unknown
-
2019
- 2019-10-04 US US16/593,147 patent/US11180466B2/en active Active
- 2019-12-10 JP JP2019222558A patent/JP6933702B2/en active Active
-
2021
- 2021-08-19 JP JP2021133844A patent/JP7241134B2/en active Active
- 2021-09-29 US US17/488,568 patent/US20220017478A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020063274A (en) | 2020-04-23 |
| US11180466B2 (en) | 2021-11-23 |
| CN110016003A (en) | 2019-07-16 |
| CA3130003C (en) | 2023-08-29 |
| BR112016002027A2 (en) | 2017-08-01 |
| JP2016525561A (en) | 2016-08-25 |
| CA2919976A1 (en) | 2015-02-05 |
| US20220017478A1 (en) | 2022-01-20 |
| AU2014298433B2 (en) | 2018-08-16 |
| EP3027594A1 (en) | 2016-06-08 |
| PT3027594T (en) | 2022-11-04 |
| JP6933702B2 (en) | 2021-09-08 |
| JP2021191762A (en) | 2021-12-16 |
| CA3130003A1 (en) | 2015-02-05 |
| US10450285B2 (en) | 2019-10-22 |
| DK3027594T3 (en) | 2022-11-14 |
| CN105705496A (en) | 2016-06-22 |
| EP3027594B1 (en) | 2022-08-10 |
| JP7241134B2 (en) | 2023-03-16 |
| AU2014298433A1 (en) | 2016-02-25 |
| WO2015014972A1 (en) | 2015-02-05 |
| RU2016103654A (en) | 2017-09-04 |
| CA2919976C (en) | 2021-11-02 |
| HK1226072A1 (en) | 2017-09-22 |
| US20200031787A1 (en) | 2020-01-30 |
| US20160185740A1 (en) | 2016-06-30 |
| GB201313664D0 (en) | 2013-09-11 |
| ES2930138T3 (en) | 2022-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1220692A1 (en) | Benzimidazolone derivatives as bromodomain inhibitors | |
| ZA201603337B (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| HK1212696A1 (en) | Cdc7 inhibitors cdc7 | |
| HK1211578A1 (en) | Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1 | |
| HK1223090A1 (en) | 4-azaindole derivatives 4- | |
| HK1216531A1 (en) | Novel inhibitors | |
| GB201317609D0 (en) | Inhibitor compounds | |
| HK1222848A1 (en) | Pyrrolotriazines as alk inhibitors alk | |
| HK1213885A1 (en) | Imidazo-triazine derivatives as pde10 inhibitors pde10 - | |
| EP2968324A4 (en) | Substituted pyridizinone derivatives as pde10 inhibitors | |
| HK1226072A1 (en) | 2-benzoylaminobenzamide derivatives as bcl-3 inhibitors | |
| EP3010913A4 (en) | Piperidinyl benzoimidazole derivatives as mpge-1 inhibitors | |
| EP2945930A4 (en) | Novel ddp-iv inhibitors | |
| GB201321328D0 (en) | Inhibitor compounds | |
| GB201305503D0 (en) | Inhibitor |